CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Extra blood sampleWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation

Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug505 CYNK-001 Wiki 1.00

Correlated MeSH Terms (14)

Name (Synonyms) Correlation
D030341 Nidovirales Infections NIH 1.00
D003333 Coronaviridae Infections NIH 0.50
D012327 RNA Virus Infections NIH 0.50
D007154 Immune System Diseases NIH 0.41
D008171 Lung Diseases, NIH 0.26
D012140 Respiratory Tract Diseases NIH 0.24
D012141 Respiratory Tract Infections NIH 0.21
D011024 Pneumonia, Viral NIH 0.13
D014777 Virus Diseases NIH 0.12
D003141 Communicable Diseases NIH 0.09
D011014 Pneumonia NIH 0.06
D007239 Infection NIH 0.06
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (3)

Name (Synonyms) Correlation
HP:0002088 Abnormal lung morphology HPO 0.26
HP:0011947 Respiratory tract infection HPO 0.21
HP:0002090 Pneumonia HPO 0.06

There is one clinical trial.

Clinical Trials

1 Study of Hemostasis in Case of Severe COVID-19

The COVID-19 outbreak has led to a significant increase in the number of patients admitted to intensive care for respiratory distress. Early data indicate a particularly high risk of thrombotic risk to viral lung disease, particularly in the most severe patients, with a particularly high incidence of pulmonary embolism. Catheter thrombosis and extra-renal purification filters are also abnormally common. These thrombotic complications could contribute to the mortality observed in this pathology. The introduction of early curative anticoagulation in the most severe patients has just been proposed by the perioperative hemostasis interest group Biologically, a significant proportion of patients hospitalized in intensive care have a marked biological inflammatory syndrome, associated with signs of activation of clotting (a frank increase in D-dimers). The presence of circulating anticoagulants is common. Interestingly, thrombocytosis, normally observed in such inflammatory syndromes, is absent. In this context, it seems legitimate to explore these patients from a hemostasis perspective to identify the factors that cause this thrombotic over-risk, in order to minimize the occurrence of these complications.

NCT04359992 COVID-19 Infection Other: Extra blood sample

Primary Outcomes

Measure: Platelet activation intensity with the occurrence of clinical thrombotic complications

Time: Change of platelet activity from admission's day in intensive care unit to 2 days and 7 days

No related HPO nodes (Using clinical trials)